نتایج جستجو برای: bevacizumab avastin

تعداد نتایج: 11361  

2015
Douglas K Sigford Shivani Reddy Christine Mollineaux Shlomit Schaal

PURPOSE To report on endophthalmitis occurrence and associated risk factors following the intravitreal injection of anti-VEGF agents based on a review of published literature. MATERIALS AND METHODS A Medline search was performed using the terms "bevacizumab" and "ranibizumab". A total of 534 English-language articles of varying design and published from 2006 to November 2013 were analyzed for...

Journal: :Collegium antropologicum 2010
Ratimir Lazić Ivan Boras Marko Vlasić Nikica Gabrić Zoran Tomić

Macular edema along with macular ischemia is responsible for decreased visual acuity in central retinal vein occlusion. Bevacizumab (Avastin, Genentech) blocks vascular endothelial growth factor (VEGF) induced hyperpermeability of blood vessels. In this prospective case series we investigated the efficacy of anti-VEGF treatment in reduction of central retinal thickness (CRT) and improvement in ...

Journal: :Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 2012
Robert L Avery

I nterest in and controversy over the use of bevacizumab (Avastin; Genentech/Roche, South San Francisco, CA) for the treatment of retinopathy of prematurity (ROP) have increased dramatically after the Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP) study. Off-label bevacizumab has been used extensively for age-related macular degeneration (AMD) for more tha...

Journal: :The Laryngoscope 2017
Christopher J Chin

BACKGROUND Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, often manifests with epistaxis. The disease spectrum is wide; some patients have small, irritating bleeds, whereas other patients require monthly blood transfusions. There are many medical and surgical interventions for epistaxis in HHT, but none have been established as a gold-standard treatment. ...

2015
V Popescu C Leasu D Stana C Alexandrescu A Dumitrescu

Anti-vascular endothelial growth factor (anti-VEGF) therapy used as adjunctive to glaucoma filtration surgery may help filtering bleb survival because vascular endothelial growth factor has an important role in the angiogenesis of new vessels and in the fibrogenesis, which lead to scar formation and bleb failure. Bevacizumab is a non-selective monoclonal antibody against all isoforms of VEGF-A....

Journal: :Indian journal of ophthalmology 2007
Parag K Shah V Narendran Khaled A Tawansy A Raghuram Kalpana Narendran

Aggressive posterior retinopathy of prematurity (formerly known as fulminate/type II/rush disease) occurs in zone 1 or posterior zone 2. Treatment involves extensive near confluent laser ablation of a large area of avascular retina. Anterior segment ischemia is a rare complication that can occur due to injury to the long posterior ciliary arteries in the horizontal meridians during aggressive p...

Journal: :JAMA otolaryngology-- head & neck surgery 2013
Derek J Rogers Shilpa Ojha Rie Maurer Christopher J Hartnick

IMPORTANCE Juvenile recurrent respiratory papillomatosis (RRP) can be an aggressive disease process necessitating frequent trips to the operating room with multiple anesthetics for tumor debulking and airway preservation. Adjuvant therapy, such as that which is reported in this article, may help reduce the number of operative procedures affected children need each year and therefore may also af...

Journal: :Retina 2010
Andrés Kychenthal Paola Dorta

PURPOSE The purpose of this study was to evaluate the feasibility of performing vitrectomies after using bevacizumab (Avastin, Genentech, South San Francisco, CA) for the management of retinal detachments in retinopathy of prematurity. METHODS Eleven eyes of 8 children with retinopathy of prematurity retinal detachment that developed despite peripheral ablation with indirect diode laser were ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید